GlassScriptPhysician profile
Theodore S Roosevelt
NPI 1699754697
$64,549.81
in general payments reported to CMS, 2019-2025
34 companies · $712 in 2025
The $712 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $9,333 · 2021: $8,017 · 2022: $1,737 · 2023: $857 · 2024: $1,138 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,707.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $26,617.54 | 2019-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $12,867.78 | 2019-2020 | |
| Novo Nordisk INC | $9,420.53 | 2019-2025 | Sogroya, Ozempic, Rybelsus |
| Abbvie INC. | $6,915.97 | 2019-2025 | Synthroid |
| Corcept Therapeutics | $4,416.08 | 2019-2025 | Korlym |
| Abbott Laboratories | $691.39 | 2021-2025 | Freestyle Libre 3, Proclaim, Eterna |
| Lilly USA, LLC | $493.77 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $413.97 | 2019-2024 | Tepezza |
| Antares Pharma, INC. | $354.83 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Novartis Pharmaceuticals Corporation | $338.11 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $337.36 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $298.62 | 2019-2025 | Jardiance, Synjardy |
| Xeris Pharmaceuticals, INC. | $271.80 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Esperion Therapeutics, INC. | $148.64 | 2021-2022 | |
| Horizon Therapeutics Plc | $117.96 | 2022-2023 | Tepezza |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $115.14 | 2020-2024 | Isturisa, Signifor Lar |
| Dexcom, INC. | $89.55 | 2019-2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $89.10 | 2021-2024 | |
| Insulet Corporation | $84.93 | 2019-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $72.78 | 2020-2021 | |
| Ibsa Pharma INC. | $52.69 | 2021-2023 | Tirosint, Licart |
| Halozyme INC | $42.99 | 2023 | |
| Ascendis Pharma Endocrinology INC | $37.62 | 2025 | Yorvipath |
| Pfizer INC. | $32.77 | 2022 | |
| Medtronic, INC. | $32.65 | 2022 | |
| Amarin Pharma, INC. | $31.44 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $31.39 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $31.05 | 2024-2025 | Zenpep |
| Amryt Pharma Holdings LTD | $26.46 | 2022 | |
| Alexion Pharmaceuticals, INC. | $22.14 | 2020 | |
| Acella Pharmaceuticals, LLC | $18.68 | 2025 | NP Thyroid 60 |
| Ultragenyx Pharmaceutical INC. | $14.92 | 2021 | |
| Averitas Pharma INC. | $13.11 | 2024 | Qutenza |
| Tandem Diabetes Care, INC. | $6.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Roosevelt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.